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Abstract
Background: Gene rearrangements such as chromosomal translocations have been shown to
contribute to cancer development. Human chromosomal fragile sites are regions of the genome
especially prone to breakage, and have been implicated in various chromosome abnormalities found
in cancer. However, there has been no comprehensive and quantitative examination of the location
of fragile sites in relation to all chromosomal aberrations.
Results: Using up-to-date databases containing all cancer-specific recurrent translocations, we
have examined 444 unique pairs of genes involved in these translocations to determine the
correlation of translocation breakpoints and fragile sites in the gene pairs. We found that over half
(52%) of translocation breakpoints in at least one gene of these gene pairs are mapped to fragile
sites. Among these, we examined the DNA sequences within and flanking three randomly selected
pairs of translocation-prone genes, and found that they exhibit characteristic features of fragile
DNA, with frequent AT-rich flexibility islands and the potential of forming highly stable secondary
structures.
Conclusion: Our study is the first to examine gene pairs involved in all recurrent chromosomal
translocations observed in tumor cells, and to correlate the location o f  m o r e  t h a n  h a l f  o f
breakpoints to positions of known fragile sites. These results provide strong evidence to support
a causative role for fragile sites in the generation of cancer-specific chromosomal rearrangements.
Background
Tumor cells exhibit various forms of genomic instability,
including chromosomal rearrangements, many of which
directly contribute to the neoplastic process rather than
occurring as a consequence [1,2]. Rearrangements causing
the deletion, insertion or translocation of genetic material
often result in the expression of altered gene products
with oncogenic potential, or the loss of tumor suppressive
functions. Although the mechanisms of these processes
remain elusive, it is evident that DNA breakage is an initi-
ating event.
There are a variety of ways by which a cell acquires DNA
breaks. Breaks can arise from any agent that affects the pri-
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mary structure of the double helix, like endogenous reac-
tive oxygen species or exogenous factors such as ionizing
radiation [3]. More recent reports suggest that, in addi-
tion, regions of the genome especially susceptible to
breakage termed "fragile sites" may also cause DNA strand
breakage. One study using chromosome banding has pro-
vided compelling evidence supporting a role for fragile
sites in cancer development by demonstrating a signifi-
cant association between sites of chromosome rearrange-
ments found in tumor cells and fragile sites [4]. Therefore,
it has been proposed that fragile sites may contribute to
the genetic instability observed in cancer cells [5], but a
direct role has not yet been proven.
Fragile sites are defined as non-random chromosomal loci
that exhibit gaps and breaks on metaphase chromosomes
under conditions which partially inhibit DNA synthesis
[6]. Fragile sites are classified as common or rare, depend-
ing on their frequency in the population, and are further
divided according to their mode of induction in cultured
cells. Common fragile sites are present in all individuals,
and are therefore believed to represent a normal compo-
nent of chromosome structure [7]. In contrast, rare fragile
sites are found in less than 5% of the population, and are
inherited in a Mendelian manner [8,9]. To date, about
121 different fragile sites have been identified, but the
number may increase. The majority of fragile sites can be
induced by environmental agents and chemicals, includ-
ing caffeine, alcohol and cigarette smoke [6]. Variability of
fragile site breakage has been observed within individuals
[10], which may reflect exposure to such factors, with high
levels being associated with cancer [11]. Many genes
located within or spanning these sites have been identi-
fied as tumor suppressors or oncogenes, and fragile sites
have been found to be preferential targets of environmen-
tal mutagens and carcinogens [12]. Numerous studies
have also revealed a significant association between the
location of fragile sites and sites of a limited number of
chromosome defects in cancer cells [13-15]. Moreover,
Durkin et al. demonstrated that the deletions of the type
seen in cancer can be produced within fragile site FRA3B,
a site of rearrangements and deletions that are among the
most common type of aberrations found in tumors [16],
further supporting a role for fragile sites in cancer devel-
opment.
Although the mechanisms of fragile site breakage are still
unclear, several factors have been identified which con-
tribute to fragile site instability. Studies have shown that a
deficiency of proteins in the ATR-dependent cell cycle
checkpoint pathway dramatically increases fragile site
breakage [14]. In addition, all fragile DNA sequences
examined so far demonstrate significantly high flexibility
[17], and are comprised of AT-rich flexibility islands that
can readily fold into stable secondary structures capable of
perturbing DNA replication [17,18]. Moreover, all fragile
sites studied to date, including FRAXA [19], FRA7H [20],
FRA3B [21], FRA10B [22], and FRA16B [22] have been
identified as late-replicating regions of the genome.
It is not entirely clear why fragile sites are susceptible to
delayed replication, but it has been proposed that the flex-
ible, AT-rich DNA sequences cause the replication fork to
pause or stall at sites of secondary structure formation
[23]. Supporting this hypothesis, Zhang and Freudenreich
demonstrated that a polymorphic AT-dinucleotide repeat
capable of forming a cruciform structure within fragile site
FRA16D stalls replication fork progression in yeast, lead-
ing to increased chromosome breakage [24]. Collectively,
these results suggest a shared molecular basis among frag-
ile sites, indicating that the DNA sequences within these
regions can present significant difficulties to the replica-
tion machinery, and require the activation of DNA dam-
age checkpoint proteins. Fragile sites are therefore
believed to represent unreplicated regions of the genome
that have escaped the replication checkpoint, and are vis-
ible as gaps and breaks on metaphase chromosomes [25].
Although strong correlations have been made between the
sites of breakage in a limited number of chromosome
rearrangements and the position of fragile sites, there has
been no systematic demonstration of fragile site locations
relative to breakpoints in all known chromosome aberra-
tions. Due to the availability of extensive databases con-
taining chromosome abnormalities found in various
types of tumors, and the increasing number of fragile sites
being mapped, we have compiled a table of recurrent
translocations in which each participating gene set gener-
ates cancer-specific fusion transcripts, and mapped their
breakpoints to fragile sites. We found that in more than
half (52%) of the translocation-participating gene sets,
breakpoints within either one or both genes are located at
fragile sites. These results suggest that chromosome fragil-
ity, particularly at fragile sites, may contribute to the gen-
eration of fusion transcripts in cancer cells. Furthermore,
we have analyzed the DNA sequences at and around trans-
location-prone genes mapped to fragile sites for helix flex-
ibility and the potential to form secondary structures. Our
results demonstrate that the DNA sequences contain fre-
quent AT-rich flexibility islands, and are capable of form-
ing highly stable secondary structures, supporting their
propensity for breakage.
Results
Breakpoints in over half (52%) of gene pairs involved in 
cancer-specific recurrent translocations are mapped to 
fragile sites
To comprehensively investigate the relationship between
fragile sites and translocation breakpoints found in can-
cer, we examined all chromosome defects associated withBMC Genomics 2009, 10:59 http://www.biomedcentral.com/1471-2164/10/59
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various types of tumors, and identified recurrent translo-
cations in which translocation breakpoints in either one
or both participating genes co-localize with a fragile site.
Taking advantage of the comprehensive databases already
available, we examined a total of 444 different sets of
translocation-participating genes involved in 451 translo-
cations obtained from the "Translocation breakpoints In
Cancer database" (TICdb) [26] and Mitelman Database of
Chromosome Aberrations in Cancer [27]. We identified
all genes involved in translocations that mapped to fragile
sites, and compared the position of each breakpoint to
fragile sites (Additional file 1). The types of fragile sites,
rare or common, were also documented in Additional file
1. We found that 52 (12%) translocation-participating
gene pairs have breakpoints for which both genes co-
localize with fragile sites (Table 1), and 177 (40%) gene
sets contain one gene for which the translocation break-
point is located at a fragile site (Additional file 2). There-
fore, we concluded that a significant number (52%) of
gene pairs involved in cancer-specific recurrent transloca-
tions have at least one gene mapped to fragile sites. The
majority (65%) of translocation breakpoints are located
at common fragile sites, as opposed to rare sites. In Table
1, the partner genes in each translocation-participating
pair are specified as 5' or 3' for the position in which they
appear in the cancer-specific fusion transcript, and the
types of cancer for each gene pair are listed. Interestingly,
the table shows that some genes involved in transloca-
tions, like MLL and EWSR1, are most often found at the 5'
end of the fusion product. Our data also indicate that frag-
ile sites are involved in the abnormalities seen in a variety
of cancers including leukemias, lymphomas, and other
solid tumors, such as those of thyroid, breast, and lung.
Translocation-prone genes exhibit characteristics of 
fragile sites
Fragile sites have been shown to contain intrinsic features
within the DNA sequence that confer a predisposition to
fragility [28]. Most fragile sites sequenced to date contain
highly flexible sequences and AT-rich islands, with the
potential to form secondary structures, which are signifi-
cantly more stable than same-length random DNA
sequences [17,18]. Therefore, to determine whether genes
involved in cancer-specific recurrent translocations
exhibit properties of fragile sites, we analyzed three gene
pairs from Table 1 (CBFB/MYH11, HMGA1/LAMA4, and
MLL/AFF4), and their flanking sequences, for flexibility,
A/T content, and the propensity to form stable secondary
structures. Using the FlexStab program, we found that,
with the exception of the MYH11 locus (Figure 1), DNA
sequences with significantly high flexibility occur more
frequently within the regions harboring translocation-
prone genes than is predicted for control DNA [17]. The
control DNA, from various regions of the human genome
where no fragile sites were identified, contains approxi-
mately one high-flexibility peak every 100 kb [17]. Further
sequence composition analysis demonstrated that the
sequences within the flexibility peaks consist of a very
high A/T content (Table 2), similar to what was previously
reported for fragile site regions (78% ± 1.4%), which is
significantly different from that of nonflexible sequences
(61% ± 3.6%) (P < 0.001) [18]. In addition, these
sequences are rich in AT-dinucleotides (Table 2) to the
same extent as found in the flexible peaks of fragile site
regions (21% ± 0.5%), as compared to nonflexible DNA
(8% ± 1%) [18]. Further, the secondary structure predic-
tion analysis showed that the sequences within and sur-
rounding genes participating in cancer-specific
translocations can readily form highly stable secondary
structures, as indicated by their ΔG values (Table 2) and
predicted structures (Figure 2 and Additional file 3). Over-
all, our results demonstrate that the three gene pairs exam-
ined display characteristics of fragile DNA, which could
lead to DNA breakage, supporting the notion that fragile
sites may participate in the generation of chromosome
rearrangements.
Discussion
Research on understanding the significance of human
chromosomal fragile sites in cancer has been very active.
Fragile sites are most commonly associated with deletion
breakpoints in tumor cells, while few translocations
involving these sites have been reported. A limited
number of translocation breakpoints have been reported
near fragile sites, suggesting that chromosome fragility at
these sites may contribute to these rearrangements [29].
Our study herein provides a comprehensive survey of all
cancer-specific translocations to date. Therefore, by dem-
onstrating that breakpoints in over half (52%) of the gene
pairs co-map to fragile sites, these results provide strong
evidence to support a role for fragile sites in the genera-
tion of cancer-specific translocations. It is important to
note that we have chosen to focus on translocations and
deletions leading to fusion transcripts, and have not
included other types of rearrangements such as single
gene deletions, insertions, or complex translocations. We
have found that many of the genes examined in this study
are commonly involved in these other types of rearrange-
ments, like deletion of the FHIT gene located within frag-
ile site FRA3B, and in some cases, the same set of genes is
involved in multiple translocations observed in a variety
of cancers. An interesting observation was that some genes
located near fragile sites, such as NUP98 (11p15.4) which
participates in twenty-two different translocations exam-
ined, could not be included in Additional file 1, because
the gene was not located directly at a fragile site. Recently
described fragile sites, like FRA6H at 6p21 [30], have been
identified after discovering an association between the
chromosome location and sites of recurrent aberrations in
disorders. This suggests that 11p15.4 could be a fragile siteBMC Genomics 2009, 10:59 http://www.biomedcentral.com/1471-2164/10/59
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Table 1: Translocation breakpoints mapped to fragile sites in both partner genes of recurrent cancer-specific translocations
5'-b 3'-b
Translocationa Gene Fragile Site Gene Fragile Site Cancerc
t(2;18)(p11;q21) BCL2 FRA18B IGK@ FRA2L Diffuse large B-cell lymphoma
t(16;16)(p13;q22), inv(16)(p13q22) CBFB FRA16B, FRA16C MYH11 FRA16A Acute myeloid leukemia
inv(10)(q11q21) CCDC6 FRA10C RET FRA10G Papillary thyroid carcinoma
t(11;19)(q13;p13) CCND1 FRA11H FSTL3 FRA19B Chronic lymphocytic leukemia
t(2;7)(p11;q21) CDK6 FRA7E IGK@ FRA2L B-cell lymphoma, Chronic lymphocytic 
leukemia
t(7;11)(q21;q23) CDK6 FRA7E MLL FRA11B, FRA11G Acute lymphoblastic leukemia
t(5;7)(q35;q21) CDK6 FRA7E TLX3 FRA5G Acute lymphoblastic leukemia
t(12;22)(q13;q12) EWSR1 FRA22B ATF1 FRA12A Soft tissue tumor
t(2;22)(q33;q12) EWSR1 FRA22B CREB1 FRA2I Angiomatoid fibrous histiocytoma
inv(22)(q12q12) EWSR1 FRA22B PATZ1 FRA22B Small round cell tumor
t(6;22)(p21;q12) EWSR1 FRA22B POU5F1 FRA6H Undifferentiated bone tumor
t(2;22)(q31;q12) EWSR1 FRA22B SP3 FRA2G Ewing tumor/small round cell tumor
t(11;22)(p13;q12) EWSR1 FRA22B WT1 FRA11E Soft tissue tumor
del(4)(q12q12)d FIP1L1 FRA4B PDGFRA FRA4B Hypereosinophilic syndrome
inv(6)(p21q21) HMGA1 FRA6H LAMA4 FRA6F Pulmonary chondroid hamartoma
t(3;6)(q27;p21) HSP90AB1 FRA6H BCL6 FRA3C B-cell tumors
t(1;2)(p22;p11) IGK@ FRA2L BCL10 FRA1D B-cell lymphoma
t(2;19)(p11;q13) IGK@ FRA2L BCL3 FRA19A Mature B-cell neoplasm
t(2;3)(p11;q27) IGK@ FRA2L BCL6 FRA3C Mature B-cell neoplasm, Follicular 
lymphoma
t(2;11)(p11;q13) IGK@ FRA2L CCND1 FRA11A, FRA11H Mature B-cell neoplasm
t(2;18)(p11;q21) IGK@ FRA2L FVT1 FRA18B Follicular lymphoma
t(3;16)(q27;p12) IL21R FRA16E BCL6 FRA3C Diffuse large B-cell lymphoma
t(11;19)(q13;q13.4) MALAT1 FRA11H MHLB1 FRA19A Undifferentiated embryonal sarcoma
t(6;11)(p21.1;q13) MALAT1 FRA11H TFEB FRA6H Pediatric renal neoplasm
t(4;11)(q21.3-22.1;q23) MLL FRA11B, FRA11G AFF1 FRA4F Acute lymphoblastic leukemia, Acute 
myeloid leukemia
t(2;11)(q11;q23) MLL FRA11B, FRA11G AFF3 FRA2A Acute lymphoblastic leukemiaBMC Genomics 2009, 10:59 http://www.biomedcentral.com/1471-2164/10/59
Page 5 of 11
(page number not for citation purposes)
t(5;11)(q31;q23) MLL FRA11B, FRA11G AFF4 FRA5C Acute lymphoblastic leukemia
del(11)(q23q23)d MLL FRA11B, FRA11G ARHGEF12 FRA11B, FRA11G Acute myeloid leukemia
t(11;11)(q13;q23) MLL FRA11B, FRA11G ARHGEF17 FRA11H Acute myeloid leukemia
del(11)(q23q23)d MLL FRA11B, FRA11G CBL FRA11B, FRA11G Acute myeloid leukemia
t(11;19)(q23;p13) MLL FRA11B, FRA11G ELL FRA19B Acute myeloid leukemia
t(11;22)(q23;q13) MLL FRA11B, FRA11G EP300 FRA22A Acute myeloid leukemia
t(1;11)(p32;q23) MLL FRA11B, FRA11G EPS15 FRA1B Acute myeloid leukemia
t(6;11)(q21;q23) MLL FRA11B, FRA11G FOXO3A FRA6F Acute myeloid leukemia
t(3;11)(q25;q23) MLL FRA11B, FRA11G GMPS FRA3D Acute myeloid leukemia
t(11;14)(q23;q23) MLL FRA11B, FRA11G GPHN FRA14B Acute myeloid leukemia
t(11;19)(q23;p13.3) MLL FRA11B, FRA11G MLLT1 FRA19B Acute myeloid leukemia
t(1;11)(q21;q23) MLL FRA11B, FRA11G MLLT11 FRA1F Acute myeloid leukemia
t(9;11)(p21;q23) MLL FRA11B, FRA11G MLLT3 FRA9A, FRA9C Acute myeloid leukemia
t(11;19)(q23;p13) MLL FRA11B, FRA11G MYO1F FRA19B Acute myeloid leukemia
inv(11)(q14q23) MLL FRA11B, FRA11G PICALM FRA11F Acute myeloid leukemia
t(2;11)(q37;q23) MLL FRA11B, FRA11G SEPT2 FRA2J Acute myeloid leukemia
t(11;19)(q23;p13) MLL FRA11B, FRA11G SH3GL1 FRA19B Acute myeloid leukemia
t(6;11)(q13;q23) MLL FRA11B, FRA11G SMAP1 FRA6D Acute myeloid leukemia
t(10;11)(q21;q23) MLL FRA11B, FRA11G TET1 FRA10C Acute myeloid leukemia
t(9;9)(p21;p21) MTS2 FRA9A, FRA9C MTS1 FRA9A, FRA9C Acute lymphoblastic leukemia
inv(10)(q11q11) NCOA4 FRA10G RET FRA10G Papillary thyroid carcinoma
t(3;5)(q25;q35) NPM1 FRA5G MLF1 FRA3D Acute myeloid leukemia
t(3;6)(q27;p21) PIM1 FRA6H BCL6 FRA3C Diffuse large B-cell lymphoma
t(3;6)(q27;p21) SFRS3 FRA6H BCL6 FRA3C Follicular lymphoma
t(19;19)(p13;q13) TCF3 FRA19B TFPT FRA19A Acute lymphoblastic leukemia
inv(1)(q21q31) TPM3 FRA1F TPR FRA1K Papillary thyroid carcinoma
aThe translocation names for each unique gene set are indicated.
bPosition in which the gene appears in the cancer-specific fusion transcript
cFor a complete description, see the Mitelman database of Chromosome Aberrations in Cancer [27].
dDeletions creating a fusion between two genes
Table 1: Translocation breakpoints mapped to fragile sites in both partner genes of recurrent cancer-specific translocations (Continued)BMC Genomics 2009, 10:59 http://www.biomedcentral.com/1471-2164/10/59
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that has not yet been identified, or that the proximal frag-
ile sites FRA11C and FRA11I at 11p15.1 are larger than
previously determined. Therefore, it is appropriate to
assume that the total number of chromosomal aberra-
tions in cancer associated with fragile sites could be even
greater than presented in this study, arguing for the signif-
icance of the involvement of fragile sites in tumorigenesis.
In addition to solidifying the role of fragile sites partici-
pating in cancer development, this study also supports the
common hypothesis for the molecular basis of fragility at
these sites. We have shown that the DNA sequences
within and surrounding three pairs of translocation-prone
genes exhibit features of fragility. On average, peaks of sig-
nificantly high flexibility occur more often than in ran-
dom DNA, which is consistent with previous results [17].
We also found these peaks to have a high A/T content and
to be rich in AT-dinucleotides to the same extent as estab-
lished in fragile sites [18]. Furthermore, our data from the
MFOLD program indicate that the sequences have the
potential to form highly stable secondary structures,
another distinct characteristic of fragile sites [18], which
could disturb progression of the replication fork. Based on
our results, and the proposed mechanism of fragile site
expression, it is likely that the AT-rich flexibility islands
within or flanking translocation-prone genes are able to
stall replication by the formation of secondary structures,
which may then lead to DNA strand breakage, and ulti-
mately to chromosome rearrangements.
Several proteins involved in the replication checkpoint
pathway are essential for maintaining stability at fragile
sites [14]. These include the S phase and G2/M checkpoint
kinase ATR [25], and its downstream targets BRCA1 [31],
FACD2 [32], and CHK1 [33]. ATR is a major component
of the checkpoint pathway, where it functions by sensing
and responding to DNA damage, including stalled and
collapsed replication forks [34,35]. It is hypothesized that
ATR maintains fragile site stability by sensing and binding
to single-stranded DNA resulting from stalled replication
forks [25]. However, in the absence of ATR, the main
transducer of the DNA double-strand break (DSB) signal,
which is ATM, has been shown to regulate fragile site sta-
bility [36], indicating that DSBs also occur at fragile sites.
Following breakage, chromosome rearrangements may
take place via the homologous recombination (HR), non-
homologous end-joining (NHEJ) DSB repair pathways
[37,38], or microhomology-mediated single-strand
annealing (SSA) [39]. The repair of lesions at fragile sites
is still not clear, but evidence suggests that all three path-
ways may be involved. Based on recent observations made
by Lieber et al., it is hypothesized that the sequence-spe-
cific RAG complex involved in V(D)J recombination,
which is an important process of the NHEJ type, may also
recognize and cleave at non-B DNA structures [40], a fea-
ture shared by all fragile sites examined to date. Schwartz
et al. [41] have shown that induction of fragile sites leads
to RAD51 focus formation, and phosphorylation of DNA-
PKcs, key components of the HR and NHEJ pathways,
Table 2: Computational analysis of genes involved in cancer-specific recurrent translocations reveals characteristics of chromosomal 
fragile sites
FlexStab MFOLD
Gene Number of flexibility peaks/Kb % A/T % AT-dinucleotides Lowest ΔG valuea (kcal/mol)
CBFB 4/322 79 ± 3.9 24 ± 3.0 -116.91
MYH11 4/404 78 ± 5.5 23 ± 5.9 -97.02
HMGA1 6/259 81 ± 7.8 24 ± 3.6 -124.07
LAMA4 9/397 78 ± 2.7 23 ± 3.0 -59.2
MLL 5/339 78 ± 10.2 23 ± 4.8 -100.74
AFF4 4/338 81 ± 3.3 26 ± 3.1 -100.97
Fragile site 78 ± 1.4c 21 ± 0.5c
Control 1/100b 61 ± 3.6c 8 ± 1.0c -41.79d
aLowest ΔG value, predicted by MFOLD
bMishmar et al. [17] examined 1.1 Mb of non-fragile DNA, and showed that regions with significantly high flexibility occur every ~100 kb.
cZlotorynski et al. [18]
dThe LAMA4 sequence was randomized 1000 times to serve as a control, and then analyzed by MFOLD.BMC Genomics 2009, 10:59 http://www.biomedcentral.com/1471-2164/10/59
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DNA flexibility analysis of translocation-prone and fragile site co-localized genes Figure 1
DNA flexibility analysis of translocation-prone and fragile site co-localized genes. DNA sequences within and flank-
ing genes (A) CBFB (B) MYH11 (C) HMGA1 (D) LAMA4 (E) MLL (F) AFF4 were analyzed using the FlexStab program. The analysis 
was performed over the length of the entire gene (shaded in black) plus 125 kb flanking on each side (shaded in gray). The x 
axis indicates the size of the analyzed sequences, and the y axis shows degrees of inclination in the twist angle. Windows with 
values > 13.7° were considered as significantly high flexibility peaks [17].BMC Genomics 2009, 10:59 http://www.biomedcentral.com/1471-2164/10/59
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Secondary structure analysis of CBFB, MYH11, HMGA1, LAMA4, MLL, and AFF4 loci Figure 2
Secondary structure analysis of CBFB, MYH11, HMGA1, LAMA4, MLL, and AFF4 loci. (A) Comparison of potential to 
form secondary structure for these genes versus a control. The computed lowest free energy of predicted DNA secondary 
structures from segments of 300 nt in length, overlapping in 150 nt steps, has been fit to a curve for each gene. The Matlab 
function polyfit finds coefficients of a polynomial P(X) of degree N that fit the raw data best in a least-squares sense. The analy-
sis was performed over the length of the entire gene plus 125 kb flanking on each side. The arrows indicate where a gene 
begins and ends. The control sequence was generated by randomizing LAMA4 1000 times. The x axis indicates the size of the 
analyzed sequences, and the y axis displays the free energy of the predicted structure. Raw data plots for each gene are 
included in Additional file 3. (B) The most stable structure predicted for each gene, as produced by MFOLD. Each structure 
represents the 300 nt segment with the lowest ΔG value.
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respectively. Furthermore, they found that down-regula-
tion of RAD51 and DNA-PKcs increases fragile site insta-
bility, suggesting that both HR and NHEJ DSB repair
pathways mediate break repair at fragile sites. In addition,
the majority of breakpoints in a papillary thyroid carci-
noma rearrangement mapped to fragile sites occur at
microhomology patches, indicating that fragile site-asso-
ciated rearrangements can also arise by microhomology-
mediated SSA [42]. Although the underlying basis of chro-
mosome rearrangements is still unclear, our results show
that 39% of the translocations examined have only one
breakpoint mapped to a fragile site, suggesting that gene
rearrangements could be achieved with strand breakage at
only one gene, as well as at both participating genes. To
support this hypothesis, additional studies are needed to
obtain a greater understanding of the mechanisms of
chromosome rearrangements.
The most intriguing finding from this study is that the
majority (65%) of fragile sites mapped to translocation
breakpoints are common fragile sites, which are present in
all individuals, and can be induced by a variety of envi-
ronmental factors and chemical agents. Interestingly,
most cancers associated with the translocations examined
in this study have little or no genetic component. These
observations suggest that exposure to fragile site-inducing
chemicals and/or reduced levels of proteins critical for the
maintenance of fragile sites may confer a risk for cancer-
specific rearrangements. It will be important to identify
factors that contribute to chromosome fragility, such as
DNA sequences, proteins and environmental/dietary
agents, since fragile sites are sensitive to a range of chemi-
cals. Understanding the molecular basis of fragile sites
could therefore allow development of a prognostic assay
for cancer risk.
Conclusion
Our study is the first to comprehensively compare the
location of cancer-specific recurrent translocation break-
points and fragile sites. We showed that breakpoints in
over half (52%) of the translocation-participating gene
pairs co-map to positions of known human chromosomal
fragile sites. Furthermore, we demonstrated that the DNA
sequences at and surrounding three pairs of translocation-
prone genes that are mapped to fragile sites, exhibit fre-
quent AT-rich flexibility islands and are capable of form-
ing highly stable secondary structures, both of which are
characteristics of fragile DNA. Thus, we have provided a
greater understanding of the contribution of fragile sites
in the formation of chromosomal translocations, and fur-
ther supported a role for fragile sites in cancer develop-
ment.
Methods
Data collection
Two databases were examined encompassing all chromo-
some rearrangements found in cancer. The freely available
TICdb was downloaded from http://www.unav.es/genet
ica/TICdb/ (v2.3 May 2008), which contains the break-
points of cancer-specific reciprocal translocations mapped
to over 300 different human genes [26]. In addition, we
cross-examined the Mitelman database of Chromosome
Aberrations in Cancer, a database relating chromosomal
aberrations to tumor characteristics for recurrent translo-
cations using the Molecular Biology Associations search
tool [27]. From these databases, 444 different pairs of
genes participating in cancer-specific recurrent transloca-
tions were obtained. In some cases, the same set of genes
is involved in multiple types of translocations. All of these
translocations result in one or two cancer-specific fusion
genes. For each gene, the chromosomal locus was
obtained from the UCSC Genome Bioinformatics website
http://genome.ucsc.edu, and compared to the mapped
positions of all known fragile sites (http://
www.ncbi.nlm.nih.gov/sites/entrez?db=gene using "frag-
ile site" as a search term) [30,43-45]. All genes located at
fragile sites are highlighted in Additional file 1. The trans-
location breakpoints of all genes highlighted in Addi-
tional file 1 were compared to fragile site positions, to
identify translocations in which the site of breakage is co-
localized with a fragile site at either one (Additional file 2)
or both (Table 1) genes involved in the translocation.
Flexibility analysis
DNA helix flexibility was assessed using FlexStab, a com-
puter program designed by Mishmar et al. [17], which
measures potential local variations in DNA between con-
secutive base pairs, and is expressed as fluctuations in the
twist angle. The analysis was performed over the length of
the entire gene plus 125 kb flanking on each side, in win-
dows of 100 bp with 25 bp shift increments. Windows
with values > 13.7° were considered as significantly high
flexibility peaks [17].
Three gene pairs in which both genes are mapped to frag-
ile sites (CBFB/MYH11, HMGA1/LAMA4, and MLL/AFF4)
were used for flexibility and secondary structure analysis.
The examined sequences for each gene are: CBFB [nucle-
otides (nt) 20552249~20874160 of GenBank:
NT_010498.15],  MYH11  [nt 6985071~7388966 of
NT_010393.15],  HMGA1  [nt 24937900~25197258 of
NT_007592.14],  LAMA4  [nt 16473563~16870257 of
NT_025741.14],  MLL  [nt 21744621~22083352 of
NT_033899.7], and AFF4  [nt 34501084~34839367 of
NT_034772.5].BMC Genomics 2009, 10:59 http://www.biomedcentral.com/1471-2164/10/59
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Assessment of secondary structure
Using Zukers' MFOLD program [46], the potential of a
single-stranded DNA to form stable secondary structure
can be predicted along with its free-energy value. For a
given gene, 300 nt segments with 150 nt shift increments
were used as input for MFOLD. The length of 300 nt was
chosen because it equals the Okazaki initiation zone of
the DNA replication fork in mammalian cells, which pos-
sesses a single-stranded property during DNA replication
[47,48]. The default [Na+], [Mg2+], and temperature used
were 1.0 M, 0.0 M, and 37°C, respectively. The program
Bioperl http://www.bioperl.org/wiki/Main_Page was
used to manipulate the sequences, and Matlab (Math-
Works) was used to perform the analysis of the data.
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